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Abstract
Aims Ventilation vs. carbon dioxide production (VE/VCO2) is among the strongest cardiopulmonary exercise testing prognos-
tic parameters in heart failure (HF). It is usually reported as an absolute value. The current deﬁnition of normal VE/VCO2 slope
values is inadequate, since it was built from small groups of subjects with a particularly limited number of women and elderly.
We aimed to deﬁne VE/VCO2 slope prediction formulas in a sizable population and to test whether the prognostic power of
VE/VCO2 slope in HF was different if expressed as a percentage of the predicted value or as an absolute value.
Methods and results We calculated the linear regressions between age and VE/VCO2 slope in 1136 healthy subjects (68%
male, age 44.9 ± 14.5, range 13–83 years). We then applied age-adjusted and sex-adjusted formulas to predict VE/VCO2 slope
to HF patients included in the metabolic exercise test data combined with cardiac and kidney indexes score database, which
counts 6112 patients (82% male, age 61.4 ± 12.8, left ventricular ejection fraction 33.2 ± 10.5%, peakVO2 14.8 ± 4.9, mL/min/
kg, VE/VCO2 slope 32.7 ± 7.7) from 24 HF centres. Finally, we evaluated whether the use of absolute values vs. percentages of
predicted VE/VCO2 affected HF prognosis prediction (composite of cardiovascular mortality + urgent transplant or left ventric-
ular assist device). We did so in the entire cardiac and kidney indexes score population and separately in HF patients with se-
vere (peakVO2 < 14 mL/min/kg, n = 2919, 61.1 events/1000 pts/year) or moderate (peakVO2 ≥ 14 mL/min/kg, n = 3183, 19.9
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events/1000 pts/year) HF. In the healthy population, we obtained the following equations: female, VE/VCO2 = 0.052 × Age +
23.808 (r = 0.192); male, VE/VCO2 = 0.095 × Age + 20.227 (r = 0.371) (P = 0.007). We applied these formulas to calculate the
percentages of predicted VE/VCO2 values. The 2-year survival prognostic power of VE/VCO2 slope was strong, and it was sim-
ilar if expressed as absolute value or as a percentage of predicted value (AUCs 0.686 and 0.690, respectively). In contrast, in
severe HF patients, AUCs signiﬁcantly differed between absolute values (0.637) and percentages of predicted values (0.650,
P = 0.0026). Moreover, VE/VCO2 slope expressed as a percentage of predicted value allowed to reclassify 6.6% of peakVO2
< 14 mL/min/kg patients (net reclassiﬁcation improvement = 0.066, P = 0.0015).
Conclusions The percentage of predicted VE/VCO2 slope value strengthens the prognostic power of VE/VCO2 in severe HF
patients, and it should be preferred over the absolute value for HF prognostication. Furthermore, the widespread use of
VE/VCO2 slope expressed as percentage of predicted value can improve our ability to identify HF patients at high risk, which
is a goal of utmost clinical relevance.
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Introduction
In spite of new treatments and updated clinical management,
heart failure (HF) is still characterized by high rates of mortal-
ity and morbidity.1 Therefore, reﬁning prognostic stratiﬁca-
tion in HF is of utmost importance to guide patients’ clinical
management strategy.
Cardiopulmonary exercise testing (CPET) is a strongly
established tool to assess functional status and prognosis in
HF, so that its use is recommended to identify patients at
high risk and those eligible for heart transplant.2–5 Among
the bulk of variables provided by CPET, the most useful pa-
rameters widely recognized to assess prognosis are oxygen
consumption at peak exercise (peak VO2) and ventilatory efﬁ-
ciency assessed through the measurement of the slope of the
relationship between minute ventilation and carbon dioxide
production (VE/VCO2).
6,7 Peak VO2, proposed since 1985,
8
has long been considered the gold standard for assessing
HF severity and prognosis through CPET; however, an impor-
tant prognostic role has been more recently reported also for
VE/VCO2.
6,9 Indeed, VE/VCO2 slope has been proven strongly
associated with pulmonary and cardiac function and with pul-
monary haemodynamics and prognosis.9–11
Peak VO2 data are reported either as absolute values or as
percentages of a normal predicted value. The latter is nowa-
days preferred in the general HF population for HF progno-
sis,10,12 although heart transplant guidelines use an
absolute/kg peak VO2 value as a cut-off.
5 Several studies have
been performed to build peak VO2 predicted values.
12–14 At
present, the most frequently applied peak VO2 prediction for-
mulas are those by Hansen et al.14 and Jones et al.15 In con-
trast, data are less deﬁned with respect to VE/VCO2. A cut-
off value of 34 was proposed a few years ago, and it is still
currently used to discriminate patients at high risk of mortal-
ity.6,16,17 However, the use of a unique, non-gender-speciﬁc,
absolute value might nowadays not be applicable to all age
groups of patients. Only a few studies, with a limited number
of subjects, have been conducted to better deﬁne VE/VCO2
slope characteristics across the normal population.18–21
Those studies reported higher values in females than in males
and a positive correlation between VE/VCO2 slope and age,
but an accepted formula for a VE/VCO2 slope predicted value
is still lacking.
Accordingly, aims of the present study were to deﬁne nor-
mal values of VE/VCO2 slope in a large population of healthy
subjects and to test whether the prognostic role of VE/VCO2
slope in the HF population would be different if expressed as
percentage of predicted value, as calculated by these equa-
tions, or as absolute value.
Methods
Population
In the ﬁrst part of the project, we assessed CPET data ob-
tained in nine of our laboratories over the last 20 years
(1998–2018). The population was represented by 1136
healthy subjects of either gender, aged between 13 and 83
years. All available maximal tests in healthy subjects were
included.
We calculated the linear regression between age and
VE/VCO2 relationship slope, in the entire population, and sep-
arately for males and females.
In the second part of the study, the equations derived
from the healthy population were applied to the metabolix
exercise combined with cardiac and kidney indexes (MECKI)
score HF population, which includes 6112 HF patients en-
rolled between 1993 and 2015 and followed in 23 Italian
HF centres.22 The MECKI score registry inclusion/exclusion
criteria and patient follow-up methodology have been
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reported elsewhere in detail.10 In brief, inclusion criteria of
MECKI score patients were previous or present HF symp-
toms and former documentation of left ventricular ejection
fraction (LVEF) <40%, unchanged HF medications for at
least 3 months, ability to perform a CPET, and no major
treatment or intervention scheduled. Exclusion criteria were
history of pulmonary embolism, moderate-to-severe aortic
or mitral stenosis, pericardial disease, severe obstructive
lung disease, exercise-induced angina, and signiﬁcant ECG
alterations, or presence of any clinical comorbidity interfer-
ing with exercise performance. Patient follow-up was per-
formed according to each centre’s protocol.
We calculated the percentage of the predicted value of
VE/VCO2 slope in the 6112 HF patients, using, as referral,
the equations found in the healthy population for males
and females. The prognostic signiﬁcance of VE/VCO2 slope
expressed as absolute value was then compared with the per-
centage of predicted value. Following the MECKI score
criteria,10 prognosis was assessed as the composite of cardio-
vascular mortality + urgent transplant or left ventricular assist
device implant.
The present research protocol complies with the Declara-
tion of Helsinki, and it was approved by the Ethical Commit-
tee of Centro Cardiologico Monzino, IRCCS (CCM-127).
Cardiopulmonary exercise test
All healthy subjects performed a progressive incremental
ramp protocol using an electronically braked cycle ergometer.
In the MECKI score registry, CPET was performed and re-
ported according to standard criteria.23 Speciﬁcally, the ma-
jority of HF patients (94%, n = 5768) performed CPET using
a ramp protocol on an electronically braked cycle ergometer,
while the remaining (6%, n = 344) performed CPET on a
treadmill with a modiﬁed Bruce protocol. Both in HF patients
and in healthy subjects, the cycle ergometer CPET protocol
was set to reach peak exercise in ~10 min, but tests were
stopped as subjects reported maximal effort.24 Peak VO2
was calculated as the 20 s average of the highest recorded
VO2, while VE/VCO2 slope was calculated as the slope of
the linear relationship between VE and VCO2 from 1min after
the beginning of loaded exercise to the end of the isocapnic
buffering period. Peak VO2 predicted value percentage was
calculated according to Hansen et al.14 Peak exercise respira-
tory exchange ratio was measured as VCO2/VO2.
Results
The population of the present study was made up of 1136
healthy subjects (773 male, 68%) and 6112 patients with HF
(5001 male, 82%). Characteristics of the healthy subjects
and results of CPETs are reported in Table 1. No differences
were found in terms of age between genders; VO2 was signif-
icantly higher in males (P < 0.001 for absolute values), and
VE/VCO2 slope was higher in females (P < 0.001).
HF patients’ characteristics are reported in Table 2 for the
entire population and for either gender separately. Treat-
ment included ACE inhibitors in 75% of cases, angiotensin re-
ceptor blockers in 19%, beta-blockers in 87%, diuretics in
80%, and mineralcorticoid receptor antagonists in 52%.2
In healthy individuals, a signiﬁcant correlation between
VE/VCO2 slope and age was found both in males and in fe-
males (P < 0.001). Linear regression between the VE/VCO2
slope of healthy subjects and their age is shown in Figure 1
for the total population (upper panel), in males (middle
panel), and in females (lower panel). Speciﬁcally, the follow-
ing regression equations were calculated: entire population
predicted VE/VCO2 = 0.080 × Age + 21.413 (r = 0.303), female
gender predicted VE/VCO2 = 0.052 × Age + 23.808 (r = 0.192),
and male gender predicted VE/VCO2 = 0.095 × Age + 20.227 (r
= 0.371). The male and female VE/VCO2 slope predictions re-
sulted signiﬁcantly different (P = 0.007).
The two gender-speciﬁc equations were used to calculate
the percentage of predicted values of VE/VCO2 in the HF pop-
ulation. Average VE/VCO2 slope and percentage of predicted
VE/VCO2 values are reported in Table 2 for the entire popula-
tion and for both genders.
HF patients were evaluated considering the entire HF pop-
ulation (n = 6112) or grouping patients according to HF sever-
ity based on peak VO2, using the cut-off value of 14 mL/min/
kg. Table 3 shows the differences between these groups.
In Table 4, we report the AUCs at 2 years of follow-up for
VE/VCO2 slope and percentage of predicted value in the total
population, dividing the population according to HF severity.
AUCs were signiﬁcantly different in HF patients with peak
VO2 < 14 mL/min/kg. Figure 2 shows the ROC in patients
with peak VO2 < 14 mL/min/kg in the left panel and with
peak VO2 ≥ 14 mL/min/kg in the right panel (P = 0.0026).
VE/VCO2 expressed as percentage of predicted value
allowed reclassifying 6.6% of patients (net reclassiﬁcation im-
provement = 0.066, P = 0.0015).
Discussion
In the present study, we built VE/VCO2 slope prediction
equations based on a large population of normal subjects,
and we applied these formulas to the MECKI score data-
base. VE/VCO2 reported as a percentage of predicted value
conﬁrmed to be a strong prognostic predictor in HF pa-
tients, but with a power similar to that observed using ab-
solute VE/VCO2 values. However, in patients with severe
HF, deﬁned as those with low peak VO2, data reported as
percentages of predicted value have a stronger prognostic
capacity.
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The formula we derived for VE/VCO2 prediction is similar
to those previously reported, but it was built on a much
larger number of healthy individuals of both genders (Table
5). We preferred to put together our own standards for a
few reasons: (i) to utilize the same laboratories used for
HF patients’ evaluation; (ii) to base our prediction on a
much larger population comprehensive of both genders
with subjects of all ages; (iii) to include data of several lab-
oratories with a prolonged recruitment time; (iv) to be sure
that subjects with any symptoms, known disease, or taking
any treatment were excluded; (v) ﬁnally, but most impor-
tantly, to exclude highly trained subjects and athletes, so
that the population analysed presumably has the same liv-
ing habits as tested patients. Accordingly, peak VO2 ob-
served in the present healthy population was 93 and 84%
of the predicted value in females and males, respectively,
as calculated on a US-based population.14
It should be acknowledged that healthy individuals were
only tested on a cycle ergometer, so that it is unknown
whether subjects tested with treadmill show a different
Table 2 Characteristics of the heart failure patients
Total population (6112) Male (5001) Female (1111) P
Age (years) 61.4 ± 12.8 61.3 ± 12.6 61.7 ± 13.5 ns
Height (cm) 169.8 ± 8.3 171.8 ± 7.2 161.1 ± 7.2 <0.001
Weight (kg) 77.4 ± 14.7 79.7 ± 13.9 67.1 ± 13.5 <0.001
NYHA I n (%) 919 (15%) 805 (16%) 114 (10%) <0.001
NYHA II n (%) 3455 (57%) 2792 (56%) 664 (60%)
NYHA III n (%) 1660 (27%) 1337 (23%) 322 (29%)
NYHA IV n (%) 75 (1%) 65 (1%) 10 (1%)
Peak VO2 (mL/min) 1148 ± 433 1209 ± 435 874 ± 287 <0.001
Peak VO2 (mL/min/kg) 14.8 ± 4.9 15.2 ± 4.9 13.2 ± 4.2 <0.001
Peak VO2 (% of predicted) 56.0 ± 17.4 54.5 ± 16.9 62.8 ± 18.2 <0.001
VE/VCO2 slope 32.8 ± 7.7 32.7 ± 7.7 33.2 ± 7.8 0.039
VE/VCO2 slope (% pred) 124.0 ± 30.7 121.7 ± 30.6 124.5 ± 30.6 0.007
Workload (watt) 83 ± 34 87 ± 35 63 ± 24 <0.001
Peak RER 1.11 ± 0.12 1.12 ± 0.12 1.10 ± 0.13 <0.001
Peak VE (L/min) 46.3 ± 14.7 48.5 ± 14.5 36.3 ± 11.3 <0.001
Peak HR (bpm) 119 ± 25 120 ± 25 121 ± 26 0.04
Periodic breathing n (%) 1028 (17%) 883 (18%) 145 (13%) <0.001
LVEF (%) 33.2 ± 10.5 32.4 ± 10.1 36.7 ± 11.6 <0.001
Haemoglobin (g/dL) 13.5 ± 1.6 13.6 ± 1.6 12.7 ± 1.3 <0.001
eGFR (mL/min/1.73 m2) 71.4 ± 23.9 72.3 ± 23.9 67.4 ± 23.6 <0.001
HR rest (bpm) 71 ± 12 71 ± 13 72 ± 12 0.008
BNP (ng/mL)a 235 [91–631] 261 [100–703] 157 [78–409] <0.001
Idiopathic aetiology n (%) 2399 (39%) 1889 (38%) 510 (46%) <0.001
Ischaemic aetiology n (%) 2794 (46%) 2518 (50%) 276 (25%)
Valvular aetiology n (%) 272 (4%) 177 (4%) 95 (9%)
ICD n (%) 1905 (3%) 1660 (33%) 245 (22%) <0.001
CRT n (%) 748 (12%) 629 (13%) 119 (11%) 0.041
Mortality rate (events/1000 pts/year) 39.2 41.9 26.9 0.06
NYHA, New York Heart Association class; peak VO2, oxygen uptake at peak exercise; VE/VCO2 slope, ventilatory efﬁciency by means of CO2
production/ventilation relationship; RER, respiratory exchange ratio; VE, ventilation; HR, heart rate; eGFR, glomerular ﬁltration rate esti-
mated by modiﬁcation of diet in renal disease formula; BNP, brain natriuretic peptide; ICD, implantable cardiac deﬁbrillator; CRT, cardio
resynchronization therapy.
aBNP value was available in 2774 cases.
Table 1 Characteristics of the healthy subjects
Total population (1136) Male (773) Female (363) P
Age (years) 44.9 ± 14.5 45.2 ± 14.6 44.4 ± 14.3 ns
Weight (kg) 72.5 ± 13.8 78.2 ± 11.6 60.3 ± 9.6 <0.001
Height (cm) 172.6 ± 10.3 176.4 ± 9.4 164.5 ± 6.9 <0.001
Peak VO2 (mL/min) 2287 ± 799 2636 ± 709 1550 ± 355 <0.001
Peak VO2 (mL/min/kg) 31.7 ± 9.8 34.2 ± 10.0 26.2 ± 6.5 <0.001
Peak VO2 (% of predicted) 94.4 ± 22.2 84.2 ± 24.1 92.6 ± 18.5 0.035
VE/VCO2 slope 25.0 ± 3.8 24.5 ± 3.7 26.1 ± 3.9 <0.001
Workload (watt) 175 ± 74 203 ± 70 115 ± 36 <0.001
Peak RER 1.3 ± 0.1 1.3 ± 0.1 1.1 ± 0.1 ns
Peak VE (L/min) 74.9 ± 25.5 84.2 ± 24.1 55.3 ± 15.1 <0.001
Peak HR (bpm) 157 ± 22 158 ± 22 156 ± 21 ns
Peak VO2, oxygen uptake at peak exercise; VE/VCO2 slope, ventilatory efﬁciency by means of CO2 production/ventilation relationship; RER,
respiratory exchange ratio; VE, ventilation; HR, heart rate.
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Figure 1 Linear regression between VE/VCO2 and age in the total population and according to gender. Equations describing the linear regression be-
tween VE/VCO2 and age in all healthy subjects (upper panel), in males (middle panel) and in females (lower panel) are reported.
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VE/VCO2 relationship. However, two of the previous predic-
tion formulas were based only on subjects exercising on a
treadmill.21,25 The values obtained for a 50-year-old subject
with our equations are in between those reported by these
two studies. Moreover, both in healthy individuals and in
MECKI score patients, we used a ramp exercise protocol
Table 3 Characteristics of patients according to heart failure severity
VO2 ≥ 14 mL/min/kg (n = 3183) VO2 < 14 mL/min/kg (n = 2919) P
Age (years) 58.0 ± 12.8 65.1 ± 11.6 <0.001
Gender (male) 2768 (89%) 2233 (76%) <0.001
Height (cm) 170.8 ± 8.1 168.7 ± 8.4 <0.001
Weight (kg) 77.5 ± 13.9 77.3 ± 15.5 ns
NYHA I n (%) 748 (23%) 171 (5%) <0.001
NYHA II n (%) 1908 (60%) 1544 (53%)
NYHA III n (%) 506 (16%) 1147 (39%)
NYHA IV n (%) 18 (1%) 57 (2%)
Peak VO2 (mL/min) 1422 ± 391 851 ± 234 <0.001
Peak VO2 (mL/min/kg) 18.4 ± 4.0 11.0 ± 2.0 <0.001
Peak VO2 (% of predicted) 66.0 ± 15.0 45.1 ± 12.7 <0.001
VE/VCO2 slope 29.9 ± 5.6 35.9 ± 8.5 <0.001
VE/VCO2 slope (% of predicted) 114.7 ± 23.6 134.1 ± 34.1 <0.001
Workload (watt) 60.9 ± 25.1 40.7 ± 18.4 <0.001
Peak RER 1.12 ± 0.11 1.10 ± 0.13 <0.001
Peak VE (L/min) 53.1 ± 14.4 38.8 ± 11.2 <0.001
Peak HR (bpm) 127 ± 23 111 ± 24 <0.001
Periodic breathing n (%) 365 (%) 660 (23%) <0.001
LVEF (%) 34.4 ± 10.2 31.9 ± 10.7 <0.001
Haemoglobin (g/dL) 13.8 ± 1.5 13.1 ± 1.6 <0.001
eGFR (mL/min/1.73m2) 77.4 ± 22.5 65.2 ± 23.8 <0.001
HR rest (bpm) 70 ± 12 71 ± 13 <0.001
BNP (ng/mL) 160 [73–462] 340 [122–801] <0.001
Idiopathic aetiology n (%) 1417 (46%) 977 (34%) <0.001
Ischaemic aetiology n (%) 1319 (41%) 1471 (50%)
Valvular aetiology n (%) 110 (3.5%) 162 (6%)
ICD n (%) 877 (28%) 1026 (35%) <0.001
CRT n (%) 303 (10%) 442 (15%) <0.001
Mortality rate (events/1000 pts/year) 19.9 61.1 <0.001
LVEF, left ventricular ejection fraction; Peak VO2, oxygen uptake at peak exercise; VE/VCO2 slope, ventilatory efﬁciency by means of CO2
production/ventilation relationship; GFR, glomerular ﬁltration rate estimated by modiﬁcation of diet in renal disease formula; BNP, brain
natriuretic peptide, NYHA, New York Heart Association class; ICD, implantable cardiac deﬁbrillator; CRT, cardio resynchronization therapy.
Table 4 AUC at 2 years of follow-up for VE/VCO2 slope and percentage of predicted value in the total population and according to heart
failure severity
VE/VCO2 slope VE/VCO2 slope percentage of predicted value P
Entire population 0.686 0.690 ns
Peak VO2 < 14 mL/min/kg 0.637 0.650 0.0026
Peak VO2 ≥ 14 mL/min/kg 0.658 0.655 ns
Peak VO2, oxygen uptake at peak exercise; VE/VCO2 slope, ventilatory efﬁciency by means of CO2 production/ventilation relationship.
Table 5 Regressions proposed to calculate predicted VE/VCO2 slope
Paper N (male/female) Male Female Age Ergometer
Salvioni 2019 1136 (773/363) Y = 0.095*age + 20.2 Y = 0.052*age + 23.8 13–83 Cycle ergometer
SHIP (Koch 2009) 534 (253/281) Y = (-1.5*age + 0.5*age2 +
2.5sex-0.5*age*sex) + 22a
25–80 Cycle ergometer
Kleber 2000 101 (45/56) Y = 0.13*age + 19.9 Y = 0.12*age + 24.4 16–75 Treadmill
Neder 2001 120 (60/60) Y = 0.12*age + 21 Y = 0.08*age + 25.2 20–80 Cycle ergometer
Poulin 1994 224 (128/96) Y = 0.29*age + 7.69 Y = 0.20*age + 10.08 55–86 Treadmill
Sun 2002 474 (310/164) Y = (0.082*age 
0.0723*height) + 34.38
37–74 Cycle ergometer/
treadmill
aAge was graded in ﬁve classes (25–35, 35–44, 45–54, 55–64, and ≥64 years) and coded for the calculation.
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aimed at achieving peak exercise in about 10min, a detail not
clear in all previous studies in normal subjects. As regards HF
patients, it is of note that MECKI score patients included a mi-
nority of cases who performed a CPET on a treadmill (6%).
However, results were very similar with and without those
cases, so that we decided to report results regardless of the
ergometer used.
We applied our VE/VCO2 prediction equation to HF pa-
tients enrolled in the MECKI score database. The MECKI score
database is an established multicentre Italian registry, ﬁrst
published in 2013, that comprehends HF patients who
underwent maximal CPET.10 So far, 6112 patients have been
enrolled, with a median follow-up of 3.67 years (1341 days,
interquartile range 630–2353 days). The MECKI score registry
was undertaken to assess the risk of cardiovascular mortality,
urgent heart transplant, and left ventricular assist device in
HF patients able to perform a CPET. The MECKI score data-
base is constantly updated, and 24 HF units have contributed
to the database by sharing their results so far.22
The prognostic power of the VE/VCO2 slope we observed
conﬁrms the strong prognostic capability of this measure-
ment, similar to that previously reported in several stud-
ies.9,16,17 Except for the report by Kleber et al.,21 previous
studies and guidelines used the absolute value of VE/VCO2
slope, and speciﬁcally, the value of 34 was suggested. How-
ever, it is well known that the slope of the VE/VCO2 relation-
ship in normal subjects is gender speciﬁc and increases with
age. Interestingly, Sinagra et al.,26 in a population of young pa-
tients with cardiomyopathy (age 50 ± 11 years), reported a
VE/VCO2 prognostic cut-off value of 29, lower than the gener-
ally used 34, but understandable considering the young age
and the prevalent male gender. Similarly, Magrì et al. reported
a VE/VCO2 prognostic cut-off value of 31 for patients with hy-
pertrophic cardiomyopathy.27 Recently, age-dependent
VE/VCO2 slope prognostic cut-off values for HF patients have
been suggested, with a different value for preserved and re-
duced LVEF HF patients.28 It is of note that VE/VCO2 slope is in-
cluded in a few scores as a continuum, avoiding any cut-off
value.10,29 To group patients for HF severity, we used a peak
VO2 cut-off value of 14 mL/min/kg. The choice of this value is
totally arbitrary and based on historical reasons,30 and an ab-
solute peak VO2 value (12/14 mL/min/kg) is still used by HF
transplant guidelines.2 Notably, the group identiﬁed by peak
VO2 < 14 mL/min/kg showed several parameters suggestive
of a more severe HF, such as LVEF, haemoglobin, kidney func-
tion, and Brain Natriuretic Peptide (Table 3). Finally, and by
chance, the cut-off value of 14 mL/min/kg allowed to identify
two groups of almost equal size.
In HF patients with moderate HF, as evaluated by peak VO2
≥ 14mL/min/kg, the prognostic power of VE/VCO2 reported as
an absolute value or as a percentage of predicted value are ba-
sically the same. This may be due to the overall low event rate
in patients with moderate HF and by the low number of fe-
males. Indeed, in females, peak VO2 as an absolute value is
generally low, but prognosis is better.31–33 Different consider-
ations must be made for patients with peak VO2< 14mL/min/
kg. In this population, characterized by more events, a higher
number of females, and an older age, the use of VE/VCO2 slope
Figure 2 Receiver operating curves in patients with severe heart failure at a 2-year follow-up. The area under the curve (AUC) of VE/VCO2 in patients
with peak VO2 < 14 mL/min/kg was signiﬁcantly different if expressed as absolute value or as percentage of the predicted value (P = 0.0026).
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as a percentage of predicted value signiﬁcantly increased its
prognostic power, and it allowed correctly reclassifying 6.6%
of cases. Notably, patients with severe HF are those who need
a more precise prognosis. Accordingly, we strongly suggest
that VE/VCO2 slope is reported as a percentage of predicted
value at least in this category of HF patients.
The present study has some important limitations that
need to be acknowledged. First, patients were in stable clini-
cal condition and therapeutic regimen since at least 3months
so that patients with recent clinical instabilization were not
analysed. Second, patients with preserved LVEF were not
evaluated34–36; consequently, our results cannot be extrapo-
lated to these patient populations. Third, variables used for
risk calculation were collected at enrolment, giving a static
picture of the patients without accounting for possible
changes in clinical status and management with potential
prognostic impact, such as device implantation and changes
in HF medications. Fourth, the lack of treadmill as an ergom-
eter in the healthy subjects, as well as the small number of HF
patients tested with a treadmill, limits the applicability of our
formula to treadmill cases. Fifth, we built the VE/VCO2 predic-
tion equation from—and applied it to—subjects who
underwent an exercise protocol characterized by a progres-
sively increasing workload aimed at achieving peak exercise
in ~10 min. Consequently, the application of these prediction
equations to different protocols or to exercise tests of differ-
ent durations may be erroneous, although it has been shown
that VE/VCO2 slope in a ramp protocol is independent of ex-
ercise tolerance.24 Finally, the population of HF subjects
comes from a single country (Italy), and racial variables are
not taken into account. Therefore, the results obtained in this
population could not be extrapolated to a population of dif-
ferent ethnicity.
In conclusion, we propose a new prediction equation for
VE/VCO2 slope, based on a large population of healthy sub-
jects of both genders. We also showed that VE/VCO2 slope
percentage of predicted value strengthens the prognostic
power of VE/VCO2 slope in HF patients with severe exercise
performance impairment. Accordingly, percentage of pre-
dicted VE/VCO2 slope value should be preferred to its abso-
lute value for HF prognosis prediction in patients with
history of low LVEF.
Statistical analysis
Quantitative variables were reported as mean ± SD or median
and interquartile range as appropriate. Categorical variables
were reported as frequency and percentage. Linear regres-
sion analysis was performed to assess the best ﬁtting linear
relationship between VE/VCO2 slope and age. Differences be-
tween male and female regression equations were analysed
by a linear model including the interaction factor by age
and gender. The equations found, calculated separately in
males and females, were then used for the prediction of nor-
mal values (VE/VCO2 slope percentage) in the HF population.
Receiver operating characteristic (ROC) curves were calcu-
lated, and the area under the ROC curve (AUC) with 95% CI
was used to compare the prognostic power of VE/VCO2 slope
and of VE/VCO2 slope percentage at 2 years. Net reclassiﬁca-
tion improvement was employed to assess the potential of
VE/VCO2 percentage to improve risk prediction in comparison
to VE/VCO2 as absolute value. All statistics were performed
with SPSS for windows (IBM SPSS Statistics 25).
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